PDIA3 and cancer: Since ER homeostasis together with the expression of many ER proteins, such as GRP78, CLX (calnexin), and ERp57, are frequently altered and dysregulated in many cancer types such as neuroectodermal and hepatic cancers, conferring cell growth advantages and resistance to death, this compartment could be conceivably considered a potential target for cancer therapies.